Skip to content

SONNET BIOTHERAPEUTICS HOLDINGS, INC.: 10-Q filed 2025-02-13

What SONNET BIOTHERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2025-02-13 (fiscal Q1 2024): 31 published measures, 63 facts as tagged in accession 0001493152-25-006436.

This filing

Form
10-Q (quarterly report)
Filed
2025-02-13
Fiscal period
fiscal Q1 2024
Accession
0001493152-25-006436 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SONNET BIOTHERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-317,182,027USD
At 2024-09-302,771,030USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-12-313,145,458USD
At 2024-09-303,256,769USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-314,036,569USD
At 2024-09-30-485,739USD
At 2023-12-312,572,459USD
At 2023-09-30-225,980USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-3,160,706USD92
2023-10-01 to 2023-12-31-1,168,509USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-2,910,246USD92
2023-10-01 to 2023-12-31-3,091,737USD92

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-10-01 to 2024-12-311,000,000USD92
2023-10-01 to 2023-12-3118,626USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-10-01 to 2024-12-317,622,293USD92
2023-10-01 to 2023-12-313,838,870USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-120,841,691USD
At 2024-09-30-117,680,985USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-10-01 to 2024-12-312,022,818shares92
2023-10-01 to 2023-12-31474,699shares92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-10-01 to 2024-12-312,022,818shares92
2023-10-01 to 2023-12-31474,699shares92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1.56USD/shares92
2023-10-01 to 2023-12-31-2.46USD/shares92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1.56USD/shares92
2023-10-01 to 2023-12-31-2.46USD/shares92

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-10-01 to 2024-12-31158,400USD92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-12-3117,312USD
At 2024-09-3020,523USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-10-01 to 2024-12-3160,395USD92
2023-10-01 to 2023-12-3150,005USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-2,849,422USD92
2023-10-01 to 2023-12-31-1,278,871USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-12-316,725,163USD
At 2024-09-302,117,943USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-313,121,824USD
At 2024-09-303,210,196USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-12-311,639,981USD
At 2024-09-302,183,416USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-10-01 to 2024-12-313,849,422USD92
2023-10-01 to 2023-12-311,297,497USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-10-01 to 2024-12-311,886,076USD92
2023-10-01 to 2023-12-31644,042USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-313,007,431shares
At 2024-09-30650,284shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-12-31124,877,960USD
At 2024-09-30117,195,181USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-31104,435USD
At 2024-09-30123,417USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-31213,059USD
At 2024-09-30494,147USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-12-311,196,868USD
At 2024-09-301,206,409USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-3,002,306USD92
2023-10-01 to 2023-12-31-1,168,509USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-311,963,346USD92
2023-10-01 to 2023-12-31653,455USD92

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-10-01 to 2024-12-313,211USD92
2023-10-01 to 2023-12-313,211USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-10-01 to 2024-12-317,711,161USD92
2023-10-01 to 2023-12-313,838,870USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-635,568USD92
2023-10-01 to 2023-12-31-465,735USD92

Inspect the source

Entity
SONNET BIOTHERAPEUTICS HOLDINGS, INC. / CIK 0001106838
Captured
2026-09-21T17:18:22.439Z
SEC response SHA-256
3f4ed3e191d870392f866d0b7de79fd0378ba4f8669f59d59de1a0b18cd3dce4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106838.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))